Welcome to our dedicated page for Elevation Oncolo SEC filings (Ticker: ELEV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking a clinical-stage biotech like Elevation Oncology can feel overwhelming—every 10-K details cash runway for ADC trials, each 8-K flags fresh study data, and Form 4s reveal when executives trade shares. If you have ever typed “Elevation Oncology SEC filings explained simply” or “where to find Elevation Oncology quarterly earnings report 10-Q filing,” you already know the challenge.
Stock Titan solves it. Our AI instantly converts Elevation Oncology’s dense disclosures into clear language, highlighting R&D spend, Claudin 18.2 and HER3 program updates, and milestone payments so you can focus on decisions, not page counts. Whether you need the Elevation Oncology annual report 10-K simplified, a quick read-out of the latest Elevation Oncology 8-K material events explained, or real-time alerts on Elevation Oncology Form 4 insider transactions, we have you covered.
All filings arrive seconds after EDGAR posts, organized by form type and paired with:
- AI-powered summaries that decode complex clinical terminology
- Red-flag detection on liquidity, trial risks, and dilution
- Side-by-side views of prior quarters for easy trend analysis
Common questions answered naturally: “How do I monitor Elevation Oncology executive stock transactions Form 4? Click the Insider tab. “Need the latest Elevation Oncology earnings report filing analysis? Open our 10-Q dashboard.” From Elevation Oncology proxy statement executive compensation tables to “understanding Elevation Oncology SEC documents with AI,” every angle is covered in one place.
Stop parsing PDFs line by line. Let Stock Titan surface the trial milestones, licensing terms, and insider moves that move ELEV.
Nasdaq Stock Market LLC has filed Form 25 with the SEC to remove Elevation Oncology, Inc. (ELEV) common stock from listing and registration under Section 12(b) of the Securities Exchange Act of 1934.
The notification, signed by AVP Tara Petta on 23 Jul 2025, states that Nasdaq has reasonable grounds to believe it satisfies all requirements for the filing and has complied with its own rules pursuant to Rule 12d2-2.
Once effective, the filing will strike the company’s sole listed security—its common stock—from Nasdaq’s official list and terminate its Section 12(b) registration.
Elevation Oncology (ELEV) has ceased to be a public company. On 23-Jul-2025, Concentra Biosciences closed its acquisition via a Section 251(h) short-form merger after its subsidiary accepted 67.09% of shares tendered at $0.36 cash per share plus one non-transferable contingent value right (CVR). All remaining shares were converted into the same consideration at the effective time.
Immediately following the closing, ELEV requested Nasdaq suspend trading and filed for delisting (Form 25) and deregistration (Form 15). All equity awards were treated per the merger terms: in-the-money options received cash for intrinsic value plus a CVR; out-of-the-money options were cancelled; RSUs vested and received cash and a CVR; 22.05 m warrants were cashed out at their Black-Scholes value.
The transaction triggered a change in control. All six legacy directors resigned and Concentra’s slate, led by Kevin Tang (CEO), assumed board and officer roles. Interim CEO/CFO Tammy Furlong was terminated without cause and entered a separation agreement providing 12 months base salary, 100% target bonus, an additional $600k cash payment and full accelerated vesting.
The certificate of incorporation and bylaws were amended and restated, completing ELEV’s transition to a wholly owned Concentra subsidiary.
FAQ
What is the current stock price of Elevation Oncolo (ELEV)?
What is the market cap of Elevation Oncolo (ELEV)?
